This website is intended for healthcare professionals only. Prescribing information and adverse event reporting can be found at the bottom of this page.
This website is intended for healthcare professionals only. Prescribing information and adverse event reporting can be found at the bottom of this page.
Discover the dual effect of EVENITY: the first and only approved sclerostin inhibitor that increases bone formation and decreases bone resorption.1-4
Explore key clinical trial data, who may be appropriate for EVENITY, and how to initiate treatment.
Hear Professor Bente Langdahl, a leading investigator, explain the findings of a retrospective study of EVENITY versus teriparatide in postmenopausal women with osteoporosis at high risk of a fracture.5
To further plan your congress experience and explore everything WCO-IOF-ESCEO 2026 has to offer, speak to your local representative or access key details within this portal.
